Molecular Research on Antibody–Drug Conjugates

Dear Colleagues,

Despite substantial progress in oncology research and treatment, cancer remains a persistent global health challenge and the need for more precise diagnostic tools and enhanced therapeutic strategies is pressing. Anticancer immunotherapy drugs have shown excellent therapeutic effects in the field of cancer treatment by maximizing immune function along with strong targeting ability. In particular, over the past decade, more than 10 new antibody–drug conjugates (ADCs) have received FDA approval and entered the market. These ADCs have shown strong anticancer effects, and many researchers and pharmaceutical companies are conducting extensive investigations into and development of develop new ADCs. The success of new ADCs comes on the back of the development of antibodies that accurately recognize cancer cells and deliver a powerful payload, as well as a linker that connects them. However, ADC development still faces distinct challenges concerning the antibody, drug, and linker components. Overcoming these hurdles is crucial for creating ADCs that can precisely identify and effectively eradicate cancer cells. Therefore, in this Special Issue, we will discuss the development process of ADCs, the characteristics and limitations of current ADCs, various cancer cell targeting antibodies, and the payloads and linkers of various mechanisms.

In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.

Dr. Kwang Suk Lim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• antibody engineering
• bispecific antibodies
• payload
• cancer immunotherapy
• targeted delivery